Mesothelioma Diagnosis Improved with New Biomarkers
By LabMedica International staff writers Posted on 27 Oct 2010 |
Three important biomarkers have emerged for less invasive diagnosis of the asbestos-linked cancer mesothelioma.
Levels of a protein biomarker called mesothelin, which is found in the pleural fluid of patients with malignant mesothelioma, were studied. Mesothelin is a protein produced by mesothelioma cells and released into the fluid around the lungs.
Compared with cytology, pleural-fluid mesothelin had better sensitivity, similar specificity, and superior negative predictive value. "Pleural effusion … can be maddeningly difficult to diagnose, as a wide variety of malignant and benign causes exist,” noted Helen E. Davies, M.D., from the Oxford Pleural Unit, Oxford Center for Respiratory Medicine, University of Oxford (Oxford, United Kingdom) "One of the causes, malignant pleural mesothelioma, is a relatively rare cancer, but its incidence is rapidly increasing on a global scale.”
Calretinin is a vitamin-D dependent calcium-binding protein and another well-established immunohistochemical marker for malignant mesothelioma. A group of German researchers developed an enzyme-linked immunosorbent assay (ELISA) blood test of calretinin and tested it on 97 healthy volunteers, 35 asbestos-exposed workers and 42 mesothelioma patients. Calretinin levels were found to be elevated in both the asbestos-exposed group and among those with mesothelioma. This study appeared in the journal BMC Cancer on May 28, 2010.
A more recent report noted that the calretinin test might not be as helpful in patients who have the rare sarcomatoid type of pleural mesothelioma. A group of Danish researchers cautioned that most sarcomatoid-mesothelioma cases test negative for the presence of calretinin. Their findings were published in the September 27, 2010 edition of Ugeskr Laeger.
University of Pisa (Italy) investigators examined the value of another potential diagnostic biomarker called osteopontin, found in the plasma and serum of mesothelioma patients. After testing for osteopontin in 94 healthy volunteers, 113 patients with benign respiratory diseases (BRD) and 32 patients with malignant pleural mesothelioma, the team found levels to be "significantly higher” in patients with malignant mesothelioma than in either the healthy control group or those with BRD. The report appeared ahead of print in the September 27, 2010, edition of the International Journal of Biological Markers. The authors wrote, "Plasma and serum osteopontin may be useful markers in the diagnosis of epithelial MPM in addition to traditional radiological exams.”
Mesothelioma is very difficult to diagnose as it mimics many other conditions. It needs to be recognized early in order to treat patients appropriately and produce better outcomes. These three biomarkers should help to diagnose the dangerous condition.
Related Links:
University of Oxford
University of Pisa
Levels of a protein biomarker called mesothelin, which is found in the pleural fluid of patients with malignant mesothelioma, were studied. Mesothelin is a protein produced by mesothelioma cells and released into the fluid around the lungs.
Compared with cytology, pleural-fluid mesothelin had better sensitivity, similar specificity, and superior negative predictive value. "Pleural effusion … can be maddeningly difficult to diagnose, as a wide variety of malignant and benign causes exist,” noted Helen E. Davies, M.D., from the Oxford Pleural Unit, Oxford Center for Respiratory Medicine, University of Oxford (Oxford, United Kingdom) "One of the causes, malignant pleural mesothelioma, is a relatively rare cancer, but its incidence is rapidly increasing on a global scale.”
Calretinin is a vitamin-D dependent calcium-binding protein and another well-established immunohistochemical marker for malignant mesothelioma. A group of German researchers developed an enzyme-linked immunosorbent assay (ELISA) blood test of calretinin and tested it on 97 healthy volunteers, 35 asbestos-exposed workers and 42 mesothelioma patients. Calretinin levels were found to be elevated in both the asbestos-exposed group and among those with mesothelioma. This study appeared in the journal BMC Cancer on May 28, 2010.
A more recent report noted that the calretinin test might not be as helpful in patients who have the rare sarcomatoid type of pleural mesothelioma. A group of Danish researchers cautioned that most sarcomatoid-mesothelioma cases test negative for the presence of calretinin. Their findings were published in the September 27, 2010 edition of Ugeskr Laeger.
University of Pisa (Italy) investigators examined the value of another potential diagnostic biomarker called osteopontin, found in the plasma and serum of mesothelioma patients. After testing for osteopontin in 94 healthy volunteers, 113 patients with benign respiratory diseases (BRD) and 32 patients with malignant pleural mesothelioma, the team found levels to be "significantly higher” in patients with malignant mesothelioma than in either the healthy control group or those with BRD. The report appeared ahead of print in the September 27, 2010, edition of the International Journal of Biological Markers. The authors wrote, "Plasma and serum osteopontin may be useful markers in the diagnosis of epithelial MPM in addition to traditional radiological exams.”
Mesothelioma is very difficult to diagnose as it mimics many other conditions. It needs to be recognized early in order to treat patients appropriately and produce better outcomes. These three biomarkers should help to diagnose the dangerous condition.
Related Links:
University of Oxford
University of Pisa
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans